Notably, Novo Nordisks agreement to provide access to insulin products NovoLog and Tresiba at $35 monthly when purchased through TrumpRx reflects results from an existing Optum Rx initiative limiting out-of-pocket spend to $35 for preferred insulin products on commercial formularies enacted back in 2024
Because categories are employer-defined, companies can offer intention support without turning lifestyle benefits into an open-ended expense
Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans
First-time AOM semaglutide prescribing increased by over 50%, marking the largest quarter-over-quarter increase in first-time AOM semaglutide prescribing since mid-2024, likely driven by the approval of the oral formulation of Wegovy in December 2025
Why Families Choose Rixa Health Science-backed, compassionate, and designed for long-term results